iBIO is thrilled to start the week with an exciting announcement: Marilyn Vetter, group vice president, U.S. access strategy at Horizon Therapeutics, transitioned from vice-chair to chair of the iBIO board, and Harry Rowland, Ph.D., co-founder and chief executive officer of Endotronix, has joined as a board member. With the leadership and involvement of these industry veterans, the future of iBIO is particularly bright as we work with policy makers and our member companies to expand the life sciences community in Illinois and bring innovative therapies and successful patient outcomes. I hope you’ll take a moment to watch this video where Marilyn discusses her passion for life sciences and her personal story that brought her to our community. For more details about today’s announcement, please see our press release.